Biomedical subjects

Suzanna M Zick

Publications and source records attributed to Suzanna M Zick.

6 recordsLinked to original sources

PubMed2006

Quercetin blocks airway epithelial cell chemokine expression.

Quercetin (3,3',4',5,7-pentahydroxyflavone), a dietary flavonoid, is an inhibitor of phosphatidylinositol (PI) 3-kinase and potent antioxidant. We hypothesized that quercetin blocks airway epithelial cell chemokine expression via PI 3-kinase-dependent mechanisms. Pretreatment with quercetin and the PI 3-kinase inhibitor LY294002 each reduced TNF-alpha-induced IL-8 and monocyte chemoattractant protein (MCP)-1 (also called CCL2) expression in cultured human airway epithelial cells. Quercetin also inhibited TNF-alpha-induced PI 3-kinase activity, Akt phosphorylation, intracellular H(2)O(2) production, NF-kappaB transactivation, IL-8 promoter activity, and steady-state mRNA levels, consistent with the notion that quercetin inhibits chemokine expression by attenuating NF-kappaB transactivation via a PI 3-kinase/Akt-dependent pathway. Quercetin also reduced TNF-alpha-induced chemokine secretion in the presence of the transcriptional inhibitor actinomycin D, while inducing phosphorylation of eukaryotic translation initiation factor (eIF)-2alpha, suggesting that quercetin attenuates chemokine expression by post-transcriptional as well as transcriptional mechanisms. Finally, we tested the effects of quercetin in cockroach antigen-sensitized and -challenged mice. These mice show MCP-1-dependent airways hyperresponsiveness and inflammation. Quercetin significantly reduced lung MCP-1 and methacholine responsiveness. We conclude that quercetin blocks airway cell chemokine expression via transcriptional and post-transcriptional pathways.

Allergens↗

PubMed2006

Developing CAM Research Capacity for Complementary Medicine.

This article describes initiatives that have been central to the development of complementary and alternative medicine (CAM) research capacity in the United Kingdom, Canada and the United States over the last decade. While education and service delivery are essential parts of the development of CAM, this article will focus solely on the development of research strategy. The development of CAM research has been championed by both patients and politicians, primarily so that we may better understand the popularity and apparent effectiveness of these therapies and support integration of safe and effective CAM in health care. We hope that the perspective provided by this article will inform future research policy.

Journal Article↗

PubMed2006

Trial of Essiac to ascertain its effect in women with breast cancer (TEA-BC).

BACKGROUND: Breast cancer is a major cause of morbidity, mortality, and medical expenditures among women in Canada. Essiac (Resperin Canada Limited, Waterloo, Ontario, Canada), a blend of at least four herbs (burdock root [Arctium lappa], Indian rhubarb [Rheum palmatum], sheep sorrel [Rumex acetosella], and the inner bark of slippery elm [Ulmus fulva or U. rubra]), has become one of the more popular herbal remedies for breast-cancer treatment, secondary prevention, improving quality of life, and controlling negative side-effects of conventional breast-cancer treatment. OBJECTIVES: Our primary objective was to determine the difference in health-related quality of life (HR-QOL), as assessed by the Functional Assessment of Cancer Therapy Breast Cancer Version, between women who are new Essiac users (since breast cancer diagnosis) and those who have never used Essiac. Secondary endpoints included differences in depression, anxiety, fatigue, rate of adverse events, and prevalence of complications or benefits associated with Essiac during standard breast-cancer treatment. Additionally, we described the pattern of use of Essiac in this cohort of women. METHODS: We performed a retrospective cohort study in 510 women, randomly chosen from the Ontario Cancer Tumour Registry, with a diagnosis of primary breast cancer in 2003. RESULTS: With the exception changes in a Physical well-being subscale and a relationship with doctor subscale, Essiac did not have a significant effect on HR-QOL or mood states. Even for Physical well-being and relationship with doctor, Essiac seemed to have a negative effect, with Essiac users doing worse than the non-Essiac users. This might be attributed to the fact that the group of users comprised younger women with more advanced stages of breast cancer, and both of these subgroups of patients have been shown to be at a significantly increased risk for negative mood states and/or a decreased sense of well-being. The women were taking low doses (total daily dose 43.6 +/- 30.8 mL) of Essiac that corresponded to the label directions found on most Essiac products. Friends were the most common source of information, and most women were taking Essiac to boost their immune systems or increase their chances of survival. Only 2 women reported minor adverse events, whereas numerous women reported beneficial effects of Essiac. CONCLUSIONS: Essiac does not appear to improve HR-QOL or mood states. Future studies are needed to determine whether other clinical outcomes, such as cancer reoccurrence, are affected by Essiac.

Adult↗

PubMed2005

The prevalence and pattern of complementary and alternative supplement use in individuals with chronic heart failure.

BACKGROUND: There are few data on the prevalence and pattern of complementary and alternative medicine (CAM) supplement use among people with chronic heart failure (CHF). The aim of this survey was to characterize the prevalence, pattern, and reasons for use of CAM supplements among those with CHF. METHODS AND RESULTS: We conducted a cross-sectional survey in 2 groups: CHF patients who had participated in the Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) Trial, and CHF patients who attended the University of Michigan's CHF Outpatient Clinic. We received 252 surveys. One third of respondents had used a CAM supplement in the last 6 months. There were 24 different supplements used. Reasons for use included heart problems, anxiety, weight loss, and arthritis. No demographic or behavioral characteristic identified CAM supplement users, although a 50% lower use among HERB CHF participants approached statistical significance (P = .08). CONCLUSION: One third of our CHF patients were taking CAM supplements, several of which may interact negatively with typical heart failure medications. CAM supplement use for weight loss may be underreported. Demographic and behavioral characteristics may not have identified people with CHF who were using CAM supplements.

Adult↗

PubMed2005

Challenges in herbal research: a randomized clinical trial to assess blinding with ginger.

OBJECTIVE: To assess methods to blind study participants to encapsulated ginger (Zingiber officinale). DESIGN: A randomized double-blind placebo controlled trial. SUBJECTS: Eighty healthy male and female volunteers. OUTCOME MEASURES: Whether participants can accurately determine if they receive a ginger or placebo capsule and a bottle filled with ginger or placebo capsules. RESULTS: Forty-two subjects correctly identified the capsule they received. Of those who received placebo, over 82% correctly identified their capsule. Only 22.5% of those who received ginger correctly identified their capsule. The likelihood of guessing ginger between the groups was statistically similar (p<0.01). 65% correctly guessed which bottle they had received (p=0.0073). Participants receiving the bottle filled with ginger capsules successfully identified their bottle 75% of the time (p=0.0016) compared to the 55% of the placebo group (p=0.5). CONCLUSIONS: Volunteers cannot determine which type of individual capsule they receive but can distinguish a bottle filled with ginger capsules.

Adult↗

PubMedDate not supplied

Bridging CAM practice and research: teaching CAM practitioners about research methodology.

The National Institutes of Health (NIH) is continuing to provide funds directed to support research in complementary and alternative medicine (CAM). CAM providers typically have insufficient knowledge of scientific language or research methodology to develop rigorous proposals. Their ability to contribute meaningfully as advisors, teachers, or research partners in academic settings, is hence limited. To address this issue, we have developed and implemented a 7-week course designed to teach community-based CAM providers: (1) to understand scientific terminology, research design and grantsmanship; (2) to critically evaluate the research literature; and (3) to design pilot studies in areas of their interest. In this article, we describe the recruitment process for selecting course participants, the course design and instructional process and the evaluation results based on qualitative and quantitative methodology. We offer suggestions for developing training opportunities both at the local and national level that would increase the expertise of CAM providers in participating and seeking funded research.

Complementary Therapies↗